Related Experiment Video
Updated: Jul 9, 2026
11:34
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
RNAi for treating hepatitis B viral infection
Yong Chen1, Guofeng Cheng, Ram I Mahato
1Huai-An 4th People's Hospital, Jiangsu, China.
Pharmaceutical Research
|December 13, 2007
Summary
RNA interference (RNAi) offers a promising strategy for treating chronic hepatitis B virus (HBV) infection by silencing viral genes. This review explores methods to enhance RNAi efficacy and overcome delivery challenges for effective HBV therapy.
Area of Science:
- Molecular Biology
- Virology
- Therapeutics
Background:
- Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC).
- Current treatments like interferon-alpha and nucleotide analogues show limited success.
- There is a critical need for more effective antiviral therapies with fewer side effects.
Purpose of the Study:
- To review RNA interference (RNAi) as a potential therapeutic strategy for HBV infection.
- To discuss methods for improving the efficacy of small interfering RNA (siRNA) and small hairpin RNA (shRNA) therapies.
- To address challenges and explore delivery strategies for RNAi-based HBV treatments.
Main Methods:
- Review of existing literature on RNA interference mechanisms and applications in HBV.
- Analysis of strategies for siRNA/shRNA production and delivery.
- Discussion of barriers to RNAi-based therapies, including stability, cellular uptake, biodistribution, and off-target effects.
Main Results:
- RNAi, utilizing siRNA, shRNA, or miRNA, can silence HBV genes post-transcriptionally.
- Chemically synthesized siRNA and endogenously expressed shRNA/miRNA show potential for HBV gene silencing.
- Key challenges include poor siRNA stability, inefficient cellular uptake, biodistribution issues, and non-specific effects.
Conclusions:
- RNAi holds significant promise for developing novel, effective therapies against chronic HBV infection.
- Overcoming delivery barriers and minimizing off-target effects are crucial for successful clinical translation.
- Further research into optimized siRNA design and delivery systems is essential for advancing RNAi-based HBV treatments.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:29Viruses with RNA Genomes
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...